Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEF
NCT05512039Phase 2Active, not recruiting
- Sponsor
- Dartmouth Health
- Start
- May 2023
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in urge incontinence (2 arms), sponsored by Dartmouth Health. Primary endpoint: Change in symptom specific quality of life and bother at 3 months. Started May 2023; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
urge incontinence
Beyond the preview
Go deeper on NCT05512039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512039.